rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GNBT - Generex Biotechnology - Deel 2

2.049 Posts
Pagina: «« 1 ... 98 99 100 101 102 103 »» | Laatste | Omlaag ↓
  1. [verwijderd] 14 augustus 2008 18:28

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Durfinvest schreef:

    ~~ 0.71 USD ~~
    Oh, dank je, waardevol, hier kunnen we iets mee!
    Hopelijk krijgen we recentelijk nog menig goed nieuws!
    Maar jij zal ons hier wel op de hoogte houden, toch?
    Waarvoor hartelijk dank!
  2. [verwijderd] 18 augustus 2008 23:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0



    FDA reports deaths with diabetes drug Byetta
    Monday August 18, 4:56 pm ET
    biz.yahoo.com/ap/080818/diabetes_drug...
    By Matthew Perrone, AP Business Writer
    FDA working on new warning label for Amylin, Eli Lilly drug Byetta after deaths reported

    WASHINGTON (AP) -- Federal regulators are working on a stronger label for a widely used diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. after deaths were reported with the medication despite earlier government warnings.

    The Food and Drug Administration said Monday it has received six new reports of patients developing a dangerous form of pancreatitis while taking Byetta. Two of the patients died and four were recovering.

    Regulators stressed that patients should stop taking Byetta immediately if they develop signs of acute pancreatitis, a swelling of the pancreas that can cause nausea, vomiting and abdominal pain. The FDA warned that it is very difficult to distinguish acute pancreatitis from less dangerous forms of the condition.

    The FDA announcement updated an October alert about 30 reports of Byetta patients developing pancreas problems. None of those cases were fatal, but Byetta's makers agreed to add information about the reports to the drug's label.

    However, the FDA made clear Monday that it is seeking a stronger, more prominent warning about the risks.

    Amylin and Eli Lilly said in a statement that patients taking Byetta have shown "very rare case reports of pancreatitis with complications or with a fatal outcome." The companies added that diabetes patients are already at increased risk of pancreatitis compared with healthy patients. The pancreas produces several important biological fluids, including insulin -- the sugar-regulating hormone that most diabetics lack.

    The FDA said doctors should consider prescribing other medications to patients with a history of pancreas problems.

    Byetta competes against blockbuster drugs from GlaxoSmithKline PLC and Takeda Pharmaceuticals in the $24 billion global market for diabetes medications, according to health care research firm IMS Health.

    More than 700,000 patients with type 2 diabetes have used the injectable drug since it was launched in June 2005. It is jointly developed and manufactured by San Diego-based Amylin and Eli Lilly.

    Byetta's $636 million in sales made up about 80 percent of Amylin's total revenue last year. The drug accounted for just 3 percent of Eli Lilly's sales. The companies are developing a long-lasting version of Byetta that could be injected once weekly, instead of twice daily.

    Robert Baird & Co. analyst Thomas Russo cautioned investors that concerns about pancreatitis could affect the FDA's review and requirements for the new version. Russo rates Amylin "outperform," but said in a note to investors he could revise that rating as more information becomes available.

    Shares of Amylin Pharmaceuticals fell $4.45, or 13 percent, to $29.76 Monday, while Indianapolis-based Eli Lilly dipped 73 cents to $48.05.

    Tja!
    De grote Pharma's laten het afweten op dit gebied,
    laatst nog Pfizer!

    Pfizer haalt Exubera van de markt
    www.diabetesgroningen.nl/index.php?op...

  3. [verwijderd] 21 augustus 2008 18:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Controversies to Consensus in Diabetes, Obesity
    and Hypertension (CODHy)
    October 30 - November 2, 2008, Barcelona, Spain

    Sponsors:
    "Gold"
    www.codhy.com/2008/Document.aspx?did=76

    Generex Biotechnology Inks Glucose RapidSpray Distribution Deal in Brazil
    Thursday August 21, 9:30 am ET
    Grant of License to Brazilian International Trade Company

    WORCESTER, Mass., Aug. 21, 2008 (GLOBE NEWSWIRE) --
    biz.yahoo.com/pz/080821/148974.html

    Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, has entered into a product licensing and distribution agreement with ABP-Comercio, Importacao E Exportacao Ltda. (http://www.abptrade.com.br) for the registration, importation, marketing, distribution, and sale in Brazil of Glucose RapidSpray(tm) (http://www.glucoserapidspray.com), the Company's proprietary glucose buccal spray product.

    Glucose RapidSpray is an innovative alternative for people who want additional glucose in their diet. Glucose RapidSpray delivers a fat-free, low-calorie glucose formulation developed using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray delivers glucose directly into the buccal cavity and is simple to carry and use.

    ABP is a specialized import / export organization headquartered in Brazil.

    ``This is the first introduction of our over-the-counter product line in South America,'' said Rose Perri, Chief Operating Officer of Generex. ``Brazil offers the largest South American market for products for the treatment of diabetes and its complications and we look forward to an expanded presence in the region.''

    $0.77
    + 9%
  8. [verwijderd] 10 september 2008 17:26

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ronald76 schreef:

    Het gaat niet erg best hier.
    Dit zal wel uit gaan draaien op reverse split.

    Wie het weet mag het zeggen.

    Gr,
    0.52 USD -0.05 (-8.77 %)

    GENEREX BIOTECHNOLOGY CP DEL SEC Filing
    finance.aol.com/company/generex-biote...

    Generex Biotechnology to Present Abstracts at Scientific Symposium
    tech.insnews.org/story/siteia.shtml?S...
  9. [verwijderd] 10 september 2008 21:04

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ronald76 schreef:

    Het gaat niet erg best hier.
    Dit zal wel uit gaan draaien op reverse split.

    Wie het weet mag het zeggen.

    Gr,
    20 jan 2009
    denk het niet, plenty tijd

    ik wacht wel op wat bodemvorming af voordat ik weer wat koop
  13. [verwijderd] 12 september 2008 19:44

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    [quote=ronald76]
    Het gaat niet erg best hier.
    Dit zal wel uit gaan draaien op reverse split.

    Wie het weet mag het zeggen.

    Gr,
    [/quote]

    20 jan 2009
    denk het niet, plenty tijd

    ik wacht wel op wat bodemvorming af voordat ik weer wat koop

    Laatste koers: 0.64 USD 0.08 (14.29 %)

  17. [verwijderd] 18 september 2008 20:59

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Siejoe schreef:

    Vandaag +26% naar 0.63
    [/quote]

    [quote=SkySpam1]
    Zo te zien is er iets gaande?!
    $0.70 - $0.71

    Plus 40%
    En op de terugweg?
    $0.64 - $0.65

    Plus 30%
  18. [verwijderd] 18 september 2008 21:00

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ronald76 schreef:

    Ik kan niets vinden van nieuws,iemand die meer weet dan wij?

    Gr,
    0.65 30%
    Het enige dat ik hier kan vinden dateert van gisteren.
    Generex reaches enrollment milestone in Phase III diabetes study

    Published: 17 Sep 2008
    Generex reaches enrollment milestone in Phase III diabetes study
    Generex Biotechnology has reached the enrollment milestone of more than 200 subjects in the company's pivotal Phase III clinical trial of Generex Oral-lyn, its proprietary prandial oral insulin spray product.

    The Phase III study will involve up to 750 subjects with Type-1 diabetes mellitus. There are 74 sites in the US, Canada, Bulgaria, Poland, Romania, Russia and Ukraine actively screening and enrolling subjects.

    The objective of this long-term study is to compare the efficacy of Generex Oral-lyn and the company's RapidMist diabetes management system with prandial injections of regular human insulin as measured by HbA1c.

    The company believes that Generex Oral-lyn will offer a safe, simple, fast, effective, and pain-free alternative to prandial insulin injections, which will improve subject compliance with therapeutic regimes, thereby delaying the progress of diabetes and the onset of its myriad complications.

    Generex Oral-lyn is presently approved for commercial sale in India and Ecuador.

    Source: Datamonitor
    www.datamonitor.com/industries/news/a...
  19. [verwijderd] 18 september 2008 21:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    skippy44 schreef:

    Het enige dat ik hier kan vinden dateert van gisteren.
    Generex reaches enrollment milestone in Phase III diabetes study
    Dit kan de reden niet zijn, aangezien dit gisteren voorbeurs was gekend. En zijn gisteren bijna 6% gedaald.

    Maar is alweer op z'n terugweg!
    $0.61 - $0.62
  20. [verwijderd] 18 september 2008 22:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    SkySpam1 schreef:

    [quote=skippy44]
    Het enige dat ik hier kan vinden dateert van gisteren.
    Generex reaches enrollment milestone in Phase III diabetes study
    [/quote]
    Dit kan de reden niet zijn, aangezien dit gisteren voorbeurs was gekend. En zijn gisteren bijna 6% gedaald.

    Maar is alweer op z'n terugweg!
    $0.61 - $0.62
    Dit heb ik ook niet beweerd,doch u "opmerking"aangaande bericht was wel terecht. De koers inmiddels afgesloten op $0.70 +40%
    Ligt misschien aan het beurs sentiment van het laatste uur.
2.049 Posts
Pagina: «« 1 ... 98 99 100 101 102 103 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.120
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.176
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.857
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.840
Aedifica 3 926
Aegon 3.258 323.075
AFC Ajax 538 7.089
Affimed NV 2 6.305
ageas 5.844 109.905
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.290
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.276
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 420
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.908
AMG 971 134.357
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.057
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.806
Arcelor Mittal 2.034 320.987
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.353
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.614
ASML 1.766 110.167
ASR Nederland 21 4.512
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.937
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449